Yes, ibogaine is a psychedelic, though an atypical one. Researchers often call it oneirogenic, meaning dream-producing, because at treatment doses it brings on vivid, dream-like visions while the person remains awake. At low doses, it acts as a mild stimulant, but at the higher doses used in treatment, it produces a full psychedelic state, and many researchers describe it as a dissociative psychedelic with dream-like properties.
That profile sets ibogaine apart from psilocybin, LSD, and ayahuasca. Its effects last far longer and reach more brain systems at once. It also carries a cardiac risk that the classic psychedelics do not. The sections below explain where ibogaine fits among psychedelics and what neuroscientific research says about its dream-like state. They also walk through what patients go through during treatment, based on what our founder, Aeden Aeharn, has seen while working with more than 2,500 patients.
What Defines a Psychedelic?
Psychedelics, also called hallucinogens, are substances that temporarily change perception and mood by altering how the brain signals. The classic group, which includes LSD, psilocybin, DMT, and mescaline, works mainly through the serotonin 5-HT2A receptor. Other compounds, such as ketamine, sit at the edges of the category. Ketamine is a dissociative anesthetic, while ibogaine is an atypical psychedelic that acts on multiple receptor systems at once. Depending on the substance, people may feel detached from their body or see dream-like imagery, and many notice shifts in how they think about themselves.
Some psychedelics are derived from plants or fungi; others, like LSD, are made in a lab. Mescaline comes from peyote, psilocybin from certain mushrooms, DMT from plants such as Psychotria viridis, and ibogaine is extracted from the root bark of Tabernanthe iboga, a Central African shrub. Each class interacts with the brain’s chemical messengers differently. Classic psychedelics target serotonin, whereas ketamine blocks glutamate signaling at NMDA receptors. Ibogaine touches both of these systems, plus opioid and dopamine pathways, which helps explain why its effects feel so different.
Why Ibogaine Is Called an Oneirogenic Psychedelic
Ibogaine is one of the few psychedelics with its own subcategory, and the name comes from how patients describe it and how the brain behaves under its effects. The two subsections below cover what the term means and what lab recordings have found.
What Oneirogenic Means
Oneirogenic comes from the Greek word oneiros, meaning the personification of dreams. The term describes substances that produce a dream-like state of consciousness while a person is awake, and ibogaine is the best-known example. Patients often describe watching scenes play out behind closed eyes, much like dreaming, yet they stay aware of the room around them and can interact with staff. Dose shapes the effect: In Gabon, people have traditionally chewed small amounts of iboga root bark to fight fatigue, and at that level ibogaine works as a mild stimulant. At treatment doses, which are calculated for each patient, the visionary state takes over.
Brain Activity That Resembles REM Sleep
The dream-like label has lab evidence behind it. In a 2021 study published in ACS Pharmacology & Translational Science, González and colleagues at Uruguay’s Universidad de la República recorded brain activity in rats given ibogaine. The animals were awake, yet their cortical recordings carried traits of rapid eye movement (REM) sleep, the stage when most vivid dreaming happens. Gamma oscillations were stronger but less coherent and less complex than in normal waking. A machine-learning classifier trained to tell wakefulness from sleep labeled the ibogaine state as REM sleep in five of the six animals. The authors called it the first electrophysiological evidence of a waking, dream-like brain state produced by ibogaine.
An earlier study by the same group, published in Frontiers in Pharmacology in 2018, found that ibogaine increased wakefulness and suppressed actual REM sleep for hours. Read together, the two studies suggest ibogaine pushes REM-like activity into the waking state. That fits how patients describe it: dreaming with their eyes closed while fully awake.
These are animal studies, and human brain-imaging data on ibogaine is still limited. They do give the oneirogenic label a measurable basis, though, and help explain why patients so often revisit memories in a way that feels like a vivid dream.
How Ibogaine Differs From Traditional Psychedelics
Ibogaine differs from traditional psychedelics, such as LSD, psilocybin, and peyote, in the following ways:
Duration and Intensity
Ibogaine’s effects last far longer than those of classic psychedelics. The visionary and introspective stages usually span 20 hours or more, and residual effects, such as a reduced need for sleep, can last up to 72 hours as the body clears noribogaine, a long-acting metabolite. LSD typically lasts 8 to 12 hours, and psilocybin lasts 4 to 6 hours. The experience is physically demanding too, with nausea and loss of coordination as common side effects, which is why ibogaine should only be taken under medical supervision.
Neurochemical Impact
Classic psychedelics act mainly on one receptor, serotonin 5-HT2A. Ibogaine works on at least five targets at once. It binds to kappa-opioid and NMDA receptors and blocks the transporters that recycle serotonin and dopamine. It also affects nicotinic acetylcholine and sigma-2 receptors. Animal research shows ibogaine raises levels of glial cell line-derived neurotrophic factor (GDNF), a protein that supports dopamine neurons in the brain’s reward system. That broad profile is a likely reason ibogaine has drawn so much interest for addiction, though how much each target contributes is still being studied.
How Ibogaine Compares to Psilocybin, LSD, Ayahuasca, and Ketamine
The table below sets ibogaine beside the substances it’s most often compared with. US legal status reflects federal law as of October 2026.
| Substance | Typical duration | Main mechanism | Strength of visuals | Cardiac risk | US legal status (2026) |
| Ibogaine | 24 to 72 hours, with visions in the first 4 to 8 | Multiple targets: kappa-opioid and NMDA receptors, serotonin and dopamine transporters; long-acting metabolite noribogaine | Strong and dream-like, mostly with eyes closed | High: QT prolongation that can persist for days; requires cardiac screening and monitoring | Schedule I; state-funded research in Texas and other states |
| Psilocybin | 4 to 6 hours | Serotonin 5-HT2A agonist (as psilocin) | Moderate to strong; patterns and color shifts | Low: brief rise in heart rate and blood pressure | Schedule I; regulated state programs in Oregon and Colorado |
| LSD | 8 to 12 hours | Serotonin 5-HT2A partial agonist, with dopamine activity | Strong, often with eyes open | Low to moderate: raises heart rate and blood pressure | Schedule I |
| Ayahuasca / DMT | Ayahuasca 4 to 6 hours; smoked DMT 5 to 20 minutes | DMT acts on 5-HT2A; MAO inhibitors in ayahuasca make DMT active by mouth | Very strong and immersive | Moderate: raises blood pressure; risky with serotonergic drugs because of MAO inhibition | DMT is Schedule I; some churches have court-recognized religious exemptions for ayahuasca |
| Ketamine | About 1 to 2 hours | NMDA receptor antagonist | Mild to moderate; mainly dissociative | Moderate: temporary rise in heart rate and blood pressure | Schedule III; esketamine (Spravato) is FDA-approved for treatment-resistant depression |
Ibogaine is most often compared with ayahuasca, but they are separate substances, and ibogaine contains no DMT. Ayahuasca is a South American brew made from the Banisteriopsis caapi vine and a DMT-containing plant, usually Psychotria viridis. Ibogaine is a single alkaloid from the root bark of Tabernanthe iboga, a shrub native to Central Africa. The two come from different continents, act through different chemistry, and their durations differ by a full day or more.
Ibogaine’s Psychoactive Profile
Below is a detailed overview of ibogaine’s psychoactive profile:
Dream-like, Introspective Effects
Ibogaine’s visions tend to be personal. Many patients report scenes from their own past or symbolic images tied to their substance use, and these appear most vividly with eyes closed in a dark room. That introspective quality is what makes ibogaine useful in addiction care, because patients often revisit painful memories with more emotional distance than usual. The next section walks through how that unfolds over the course of treatment.
Modulates Dopamine, Serotonin, and Opioid Receptors
Another unique property of ibogaine is its ability to modulate dopamine, serotonin, and opioid receptors. Its interaction with dopamine and serotonergic receptors influences dopamine and serotonin levels, which affect reward-seeking mechanisms and motivation. Likewise, ibogaine’s binding affinity with opioid receptors may help reduce opioid cravings and help with opioid detoxification.
What the Ibogaine Experience Is Like
Ibogaine treatment usually unfolds in three phases. Timing varies with dose and individual metabolism, but the general shape stays consistent from patient to patient. Our founder, Aeden Aeharn, went through ibogaine treatment himself before starting Experience Ibogaine, and he has since worked with more than 2,500 patients. His observations below come from that experience.
The Acute Visionary Phase
Within 1 to 3 hours of the dose, the visionary phase begins, and it typically lasts 4 to 8 hours. Patients lie down in a quiet, dim room, since the visions are strongest with eyes closed. Many describe it as watching a film of their own life, with childhood memories and people they have lost appearing alongside moments tied to their addiction. Others see symbolic or abstract imagery. Physical effects are common as well, including nausea and loss of coordination, so patients stay in bed while medical staff monitor their heart rhythm throughout.
“Most people expect a trip. What they get is closer to a memory they can walk through. I’ve watched patients see the exact moment their use started, and for a lot of them, it’s the first time they’ve looked at it without needing to numb it.” —Aeden Aeharn, founder of Experience Ibogaine
The Long Introspective Phase
As the visions fade, usually around hour 8, a quieter stage begins that can last until about hour 20. Researchers sometimes call it the evaluative phase. Imagery gives way to reflection, and patients often report clear thinking about their relationships and the choices they want to change. Many stay awake through the night, preferring to lie still and process. Setting is very important here, since a calm private room and a trusted team make it easier to work through difficult material.
“This is the part people underestimate. The visions get the attention, but the long hours afterward are where people start making sense of what they saw. We keep the room quiet and let them think. Some want to talk, most don’t, and both are fine.” —Aeden Aeharn
The Residual Period Afterward
Residual effects can last 24 to 72 hours, sometimes longer. Many patients notice a reduced need for sleep along with mental clarity and a calmer mood, which has been linked to noribogaine remaining in the body. Patients coming off opiates should also expect a gray day, a stretch of fatigue and residual withdrawal for which our medical team provides medication. Younger patients often recover faster, while older patients may have a two-day gray day. Cardiac monitoring continues through this period because noribogaine levels stay high.
Before going home, patients receive two booster doses. These are smaller than the treatment dose and help maintain noribogaine levels in the weeks that follow, since only one full ibogaine dose is safe within a 3- to 4-month period.
“The gray day is real, and I tell everyone about it before they arrive. You feel tired and flat, and some withdrawals can linger. It passes. What usually comes after is a kind of quiet people haven’t felt in years, and that’s the window where aftercare and therapy do their best work.” —Aeden Aeharn
Therapeutic Potential of Ibogaine
Ibogaine has the potential to provide the following therapeutic benefits:
Addiction Treatment
Addiction treatment is ibogaine’s best-known use, particularly for opioid dependence. A single supervised dose can ease withdrawal symptoms and reduce cravings, which gives patients room to begin recovery work. In a 2018 New Zealand study that followed 14 patients for 12 months, Noller and colleagues reported significant drops in drug use severity scores after one ibogaine treatment. Ibogaine is a tool, and lasting results still depend on the work patients do in therapy and aftercare.
Mood Regulation and Emotional Processing
Patients often report better mood and emotional processing after treatment. Part of the explanation may be ibogaine’s action on serotonin and dopamine, along with noribogaine, which blocks serotonin reuptake for days after dosing. The introspective phase matters too, because revisiting painful memories in a supported setting can help people process them. Ibogaine can help significantly with post-traumatic stress disorder (PTSD), although therapy and integration are still needed afterward.
Potential Neuroplasticity and Cognitive Effects
Evidence on brain health is early but encouraging. In a 2024 Stanford study published in Nature Medicine, 30 Special Operations veterans with traumatic brain injuries received ibogaine alongside magnesium to protect the heart. One month later, the group showed large improvements in disability, PTSD, depression, and anxiety scores, plus gains in concentration and information processing on cognitive tests. The study had no placebo group, so larger controlled trials are still needed.
Risks and Safety Considerations
While some people have experienced a significant transformation due to ibogaine therapy, it may not be a suitable option for many due to the associated risks and safety concerns.
Cardiovascular Risks
Ibogaine’s most serious risk involves the heart. Both ibogaine and noribogaine slow the heart’s repolarization, which shows up as a prolonged QT interval on an electrocardiogram (EKG) and can lead to dangerous arrhythmias. Because noribogaine stays in the body for days, that risk can persist after the visions end. At Experience Ibogaine, every patient meets with a cardiologist and completes an EKG before treatment is approved, and heart rhythm is monitored throughout the stay.
Importance of Medical Supervision
Most ibogaine-related deaths in medical literature involved people with pre-existing heart conditions or other drugs in their system, and almost all took ibogaine without medical oversight. A supervised setting directly addresses those risks, and our medical staff provides 24/7 supervision in private rooms. We base dosing on weight, age, substances used, duration of use, liver and heart function, bloodwork, and sensitivity to a test dose, and we never push the dosing threshold into unsafe territory.
Contraindications and Drug Interactions
Heart disease and serious liver problems can rule a person out of ibogaine treatment, as can medications that prolong the QT interval. Long-acting opioids need special handling as well: patients on methadone or Suboxone must first switch to a short-acting opiate for 1 to 2 months, and fentanyl has to be flushed from the body before dosing. Pre-treatment bloodwork includes a complete test for liver function, vitamin and electrolyte levels, and a urinalysis screening for contraindicated drugs.
Key Takeaways on Ibogaine as a Psychedelic
Ibogaine is a psychedelic, specifically an oneirogenic one that produces a waking, dream-like state at treatment doses and acts as a mild stimulant at low doses. It lasts far longer than psilocybin or LSD and acts on many more brain targets. It also carries a cardiac risk that requires screening and continuous monitoring. Early research, including the 2024 Stanford veterans study, supports its potential for relief from addiction and trauma, though larger controlled trials are still needed.
Frequently Asked Questions (FAQs)
Yes. Ibogaine is classified as a psychedelic and, more specifically, as an oneirogen, a substance that produces a dream-like state while awake. At low doses it acts as a mild stimulant. At treatment doses it brings on vivid visions and long periods of introspection that set it apart from classic psychedelics like psilocybin and LSD.
Yes. Addiction treatment, particularly for opioid dependence, is ibogaine’s main use. Observational studies have found reduced withdrawal symptoms and cravings after a single supervised treatment. Experience Ibogaine also treats alcohol and gambling addiction.
Ibogaine’s effects usually unfold over 24 to 72 hours. The visionary phase lasts about 4 to 8 hours, followed by an introspective phase that can last until hour 20 or later. Residual effects such as a reduced need for sleep may continue for up to 3 days.
Ibogaine is known to interact with a variety of neurotransmitter systems rather than just bonding with a single receptor. Its interaction with serotonin and dopamine receptors may potentially contribute to restored functional activity in the region of the brain that is associated with cravings and reward processing.
Yes, ibogaine is known to induce hallucinations. Users often report seeing, feeling, or hearing things that aren’t there, usually as dream-like visuals, detailed imagery of memories, and auditory distortions. In ibogaine therapy, these visions are often considered important for introspection and for confronting trauma. They may help patients gain clarity and a new perspective, which they can build on through therapy and integration.
No. Ayahuasca is a South American brew that combines DMT with MAO-inhibiting compounds from the Banisteriopsis caapi vine, and its effects last around 4 to 6 hours. Ibogaine is a single alkaloid from the Central African shrub Tabernanthe iboga. It works through different receptors, and its effects last 24 hours or more.
No. Ibogaine is an indole alkaloid with its own chemical structure and contains no DMT. The two compounds share an indole ring, a structure also found in serotonin and many psychedelics, which is one reason they are sometimes grouped together.
Ibogaine remains a Schedule I controlled substance under federal law as of October 2026, but policy is changing rapidly. An April 2026 executive order directed federal agencies to create a Right to Try pathway for investigational psychedelics and named ibogaine specifically, and Texas has committed state funding to ibogaine clinical trials. Because the rules are changing quickly, check current regulations before making plans. Experience Ibogaine provides treatment in Mexico.
References
- Cherian KN, Faerman A, Anker LA, et al. 22 The Effect of Ibogaine on Cognitive Functioning. Journal of the International Neuropsychological Society. 2023;29(s1):898-899. doi:10.1017/S1355617723011049
- Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Therapeutic Advances in Psychopharmacology. 2016;6(2):95-98. doi:10.1177/2045125315626073
- Glick & Maisonneuve, Annals of the NY Academy of Sciences (1998)
- Marton et al., Frontiers in Pharmacology (2019)
- Davis et al., Journal of Psychedelic Studies (2017)
- Alper, Kenneth R., et al. “Fatalities temporally associated with the ingestion of ibogaine.” National Library of Medicine, January 23, 2012.
- Cherian, Kristen N., et al. “Magnesium–ibogaine therapy in veterans with traumatic brain injuries.” Nature Medicine, January 5, 2024.
- Davis, Alan K., et al. “Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.” National Library of Medicine, October 17, 2017.
- González, Joaquín, et al. “EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.” National Library of Medicine, January 11, 2021.
- González, Joaquín, et al. “Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.” Frontiers in Pharmacology, April 26, 2018.
- Koenig, Xaver, et al. “The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation.” MDPI, January 28, 2015.
- Noller, Geoffrey E., et al. “Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.” The American Journal of Drug and Alcohol Abuse, April 12, 2017.
- Ravven, Wallace. “Archive: Controversial drug shown to act on brain protein to cut alcohol use.” University of California San Francisco, January 18, 2005.
- Sliwoski, Vince. “Trump’s Executive Order on Psychedelics.” Harris Sliwoski, April 21, 2026.
